GHRP-2 vs Ipamorelin
Potent but non-selective GH secretagogue vs selective, clean GH releaser — comparing efficacy and side effect profiles in growth hormone research.
Last updated: 2026-03-08
Quick Comparison Table
| Category | GHRP-2 | Ipamorelin |
|---|---|---|
| Drug Class | Growth Hormone Releasing Peptide (hexapeptide) | Growth Hormone Releasing Peptide (pentapeptide) |
| GH Release Potency | High — one of the most potent GHRPs | Moderate — selective but less potent |
| Selectivity | Non-selective (GH, cortisol, prolactin, ghrelin) | Highly selective (GH only, minimal cortisol/prolactin) |
| Appetite Stimulation | Moderate (ghrelin receptor activation) | Minimal |
| Cortisol Elevation | Significant at higher doses | Negligible |
| Prolactin Elevation | Moderate | Negligible |
| Administration | SC injection (2-3x daily) | SC injection (2-3x daily) |
| Ideal Use Case | Maximum GH release (research) | Clean GH release without hormonal side effects |
Mechanism of Action
GHRP-2
GHRP-2 Mechanism:
GHRP-2 (D-Ala-D-2-Nal-Ala-Trp-D-Phe-Lys-NH₂) is a synthetic hexapeptide and one of the most potent growth hormone releasing peptides.
Key actions: 1. **Ghrelin receptor (GHS-R1a) activation** — Potent agonism stimulating GH release from pituitary somatotrophs 2. **Hypothalamic GHRH amplification** — Enhances endogenous GHRH signalling 3. **Somatostatin suppression** — Reduces inhibitory somatostatin tone 4. **Cortisol elevation** — Activates HPA axis at higher doses 5. **Prolactin elevation** — Modest increase via hypothalamic mechanism 6. **Appetite stimulation** — Ghrelin receptor-mediated hunger increase
GHRP-2's non-selectivity means it produces a powerful but "messy" GH release — accompanied by cortisol, prolactin, and appetite effects that may be undesirable.
Ipamorelin
Ipamorelin Mechanism:
Ipamorelin (Aib-His-D-2-Nal-D-Phe-Lys-NH₂) is a pentapeptide GH secretagogue designed for selectivity.
Key actions: 1. **GHS-R1a activation** — Selective ghrelin receptor agonism focused on GH release 2. **Dose-dependent GH release** — Linear dose-response without plateau at therapeutic doses 3. **No cortisol elevation** — Does not activate HPA axis at GH-releasing doses 4. **No prolactin elevation** — No significant effect on prolactin 5. **Minimal appetite stimulation** — Reduced ghrelin-like hunger effect vs GHRP-2/GHRP-6 6. **Maintained pulsatility** — Preserves natural GH pulse pattern
Ipamorelin was specifically designed to produce "clean" GH release — maximising the desired effect while minimising hormonal side effects.
Clinical Trial Evidence
GHRP-2 Clinical Studies
Participants: 30
Duration: Acute
GHRP-2 at 1mcg/kg IV produced peak GH of ~65 ng/mL — among the highest acute GH responses of any secretagogue.
Statistically significant
Participants: 20
Duration: 7 days
GHRP-2 restored blunted GH secretion in obese subjects. Peak GH response comparable to lean controls after 7 days.
Statistically significant
Participants: 24
Duration: Acute
GHRP-2 elevated cortisol by 35-50% and prolactin by 25-40% at GH-effective doses. Dose-dependent hormonal cross-reactivity.
Not statistically significant
Participants: 100
Duration: Acute
GHRP-2 stimulation test validated as diagnostic tool for GH deficiency. Sensitivity 95%, specificity 85%.
Statistically significant
Participants: 15
Duration: Acute
GHRP-2 + GHRH produced synergistic GH release (~3x either alone). Established combination as most potent GH stimulation protocol.
Statistically significant
Ipamorelin Clinical Studies
Participants: 24
Duration: Acute
Ipamorelin produced dose-dependent GH release without significant cortisol, ACTH, or prolactin elevation — unique among GHRPs.
Statistically significant
Participants: 161
Duration: 7 days
Ipamorelin accelerated bowel recovery after abdominal surgery. First-time meal tolerance improved by 1 day vs placebo.
Statistically significant
Participants: 0
Duration: 12 weeks
Ipamorelin increased bone mineral density and formation markers in ovariectomised rats. GH-mediated bone anabolic effect.
Statistically significant
Participants: 18
Duration: Acute
Ipamorelin showed linear GH dose-response up to 100mcg/kg without desensitisation at lower doses. Predictable pharmacodynamics.
Statistically significant
Participants: 45
Duration: 4 weeks
Ipamorelin + CJC-1295 DAC produced sustained IGF-1 elevation of 35-45% with maintained GH pulsatility. Leading combination protocol.
Statistically significant
Benefits Comparison
GHRP-2 Unique Benefits
- Highest GH release potency among GHRPs
- Validated diagnostic tool for GH deficiency
- Restores GH in obesity
- Synergistic with GHRH analogues
- Extensive pharmacological characterisation
Shared Benefits
- GH secretagogue activity via ghrelin receptor
- Enhanced sleep quality (anecdotal)
- Compatible with GHRH analogues for synergy
- Preserved GH pulsatility
Ipamorelin Unique Benefits
- Highly selective GH release (no cortisol/prolactin)
- Minimal appetite stimulation
- Linear dose-response
- Proven combination with CJC-1295
- Post-surgical bowel recovery application
Research & Evidence
GHRP-2 Research
GHRP-2 is one of the most extensively studied GHRPs in clinical pharmacology. Its use as a GH deficiency diagnostic tool is validated. However, it has not been developed as a therapeutic drug due to its non-selective hormonal effects.
Ipamorelin Research
Ipamorelin's selectivity made it the most clinically advanced GHRP, reaching Phase II trials for post-surgical ileus. Its combination with CJC-1295 is the most studied GH secretagogue protocol in the research peptide space.
Head-to-Head Analysis
Direct Comparison:
Multiple studies have compared GHRPs in dose-response analyses.
GH Release: GHRP-2 produces approximately 20-30% more GH release than Ipamorelin at equivalent doses. However, this comes at the cost of cortisol and prolactin elevation.
Selectivity: Ipamorelin's key advantage is its selectivity ratio — it produces GH release without the hormonal "noise" of cortisol, prolactin, and ACTH that accompanies GHRP-2.
Practical Choice: Researchers seeking maximum absolute GH release may prefer GHRP-2. Those seeking clean, isolated GH stimulation (particularly for protocols where cortisol elevation is contraindicated) prefer Ipamorelin.
Protocol Comparison
GHRP-2 Protocol
GHRP-2 Theoretical Protocols:
Dosing: 100-300mcg SC, 2-3 times daily. Optimal timing: 30 minutes before meals or at bedtime.
Combination: GHRP-2 + Mod GRF 1-29 (100mcg each) for synergistic GH release.
⚠️ Note: Monitor cortisol and prolactin at higher doses.
Ipamorelin Protocol
Ipamorelin Theoretical Protocols:
Dosing: 200-300mcg SC, 2-3 times daily. Most common: 200mcg 3x daily (morning, post-workout, bedtime).
Combination: Ipamorelin + CJC-1295 (no DAC) — 100mcg each, 2-3x daily. Ipamorelin + CJC-1295 DAC — 200mcg Ipa + 2mg CJC weekly.
⚠️ Note: Clean side effect profile allows higher dosing flexibility.
Safety Profiles
GHRP-2 Safety
GHRP-2 Safety:
Main concerns: Cortisol elevation (35-50%) and prolactin increase (25-40%) at GH-effective doses. Chronic cortisol elevation can cause metabolic disruption. Prolactin elevation may cause gynecomastia in males.
Appetite increase may complicate body composition goals.
Water retention at higher doses. Numbness/tingling in extremities possible.
Ipamorelin Safety
Ipamorelin Safety:
Excellent safety profile — the cleanest GHRP available. No cortisol or prolactin elevation at therapeutic doses. Minimal appetite stimulation.
Side effects: Mild water retention, occasional headache, transient numbness/tingling. All mild and dose-dependent.
Desensitisation risk lower than GHRP-6 or Hexarelin with continuous use.
The Verdict
The GHRP-2 vs Ipamorelin choice is essentially potency vs selectivity. GHRP-2 produces more absolute GH release but with cortisol, prolactin, and appetite side effects. Ipamorelin provides clean, selective GH stimulation without hormonal cross-reactivity. For most research protocols, Ipamorelin's selectivity makes it the preferred choice — particularly in combination with CJC-1295. GHRP-2 is preferred when maximum GH release is the primary objective and hormonal side effects are monitored.
Frequently Asked Questions
Conclusion
GHRP-2 and Ipamorelin represent the trade-off between potency and selectivity in GH secretagogue pharmacology. GHRP-2's raw GH-releasing power is unmatched among GHRPs but carries hormonal side effects. Ipamorelin's engineered selectivity delivers clean GH stimulation that has made it the preferred secretagogue for combination protocols. For the majority of GH research applications, Ipamorelin's selectivity advantage outweighs GHRP-2's potency advantage.
Medical Disclaimer
The information provided in this comparison is for educational and research purposes only. Neither GHRP-2 nor Ipamorelin is approved for human therapeutic use by the MHRA, EMA, or FDA. This content does not constitute medical advice. Always consult a qualified healthcare professional before considering any peptide or supplement.